Mira is bringing its version of Oxford Cancer Biomarkers' PGx test to the US in the newly launched ToxNav Advantage assay.

Myriad will launch Precise MRD with select community-based clinicians in March 2026 in breast, followed by colorectal and renal cancers later this year. The company may expand into additional cancer ...

Precision BioLogic originally developed CRYOcheck Chromogenic Factor VIII in response to a growing demand for chromogenic assays 1. Launched in 2020, it was the first commercially available, ...

HALIFAX, NS, Sept. 10, 2025 /CNW/ - Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the expanded utility of its CRYOcheck Chromogenic Factor VIII ...

Proven CRYOcheck™ Chromogenic Factor VIII assay now offers expanded utility in anticipation of emerging treatments HALIFAX, NS, Sept. 10, 2025 /PRNewswire/ -- Precision BioLogic Inc., a leading ...

INNOVANCE Antithrombin assay is a cutting-edge, ready-to-use chromogenic reagent for the automated determination of antithrombin (AT) activity. It is highly accurate even at low activity levels and ...

Dublin, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The "U.S. ATP Assay Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's ...